These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29198449)

  • 21. The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects.
    Mohamed MF; Trueman S; Feng T; Friedman A; Othman AA
    J Clin Pharmacol; 2019 Apr; 59(4):510-516. PubMed ID: 30500075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of avosentan (SPP3OI) on the pharmacokinetics of a second generation oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.
    Dieterle W; Mann J
    Int J Clin Pharmacol Ther; 2006 Dec; 44(12):668-74. PubMed ID: 17190377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial.
    Edelman AB; Cherala G; Munar MY; McInnis M; Stanczyk FZ; Jensen JT
    Contraception; 2014 Nov; 90(5):550-6. PubMed ID: 25070547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Flibanserin Treatment on Body Weight in Premenopausal and Postmenopausal Women with Hypoactive Sexual Desire Disorder: A Post Hoc Analysis.
    Kornstein SG; Simon JA; Apfel SC; Yuan J; Barbour KA; Kissling R
    J Womens Health (Larchmt); 2017 Nov; 26(11):1161-1168. PubMed ID: 28817365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial.
    Goldfischer ER; Breaux J; Katz M; Kaufman J; Smith WB; Kimura T; Sand M; Pyke R
    J Sex Med; 2011 Nov; 8(11):3160-72. PubMed ID: 21933348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pharmacodynamic effects of combined administration of flibanserin and alcohol.
    Stevens DM; Weems JM; Brown L; Barbour KA; Stahl SM
    J Clin Pharm Ther; 2017 Oct; 42(5):598-606. PubMed ID: 28608926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of ethinylestradiol and levonorgestrel after administration of two oral contraceptive preparations.
    Carol W; Klinger G; Jäger R; Kasch R; Brandstädt A
    Exp Clin Endocrinol; 1992; 99(1):12-7. PubMed ID: 1628691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers.
    Menon S; Riese R; Wang R; Alvey CW; Shi H; Petit W; Krishnaswami S
    Clin Pharmacol Drug Dev; 2016 Sep; 5(5):336-42. PubMed ID: 27138968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel.
    Olsson B; Landgren BM
    Clin Ther; 2001 Nov; 23(11):1876-88. PubMed ID: 11768839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ziprasidone and the pharmacokinetics of a combined oral contraceptive.
    Muirhead GJ; Harness J; Holt PR; Oliver S; Anziano RJ
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):49S-56S. PubMed ID: 10771454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In Vivo Formation of Ethinylestradiol After Intramuscular Administration of Norethisterone Enantate.
    Friedrich C; Berse M; Klein S; Rohde B; Höchel J
    J Clin Pharmacol; 2018 Jun; 58(6):781-789. PubMed ID: 29522253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles.
    Kuhnz W; Staks T; Jütting G
    Contraception; 1993 Dec; 48(6):557-75. PubMed ID: 8131397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
    Griffith SG; Dai Y
    Clin Ther; 2004 Dec; 26(12):2056-65. PubMed ID: 15823769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers.
    Bartoli A; Gatti G; Cipolla G; Barzaghi N; Veliz G; Fattore C; Mumford J; Perucca E
    Epilepsia; 1997 Jun; 38(6):702-7. PubMed ID: 9186253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
    Devineni D; Manitpisitkul P; Vaccaro N; Bernard A; Skee D; Mamidi RN; Tian H; Weiner S; Stieltjes H; Sha S; Rothenberg P
    Int J Clin Pharmacol Ther; 2015 Jan; 53(1):41-53. PubMed ID: 25345427
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended-Cycle Levonorgestrel/Ethinylestradiol and Low-Dose Ethinylestradiol (Seasonique(®)): A Review of Its Use as an Oral Contraceptive.
    Burness CB
    Drugs; 2015 Jun; 75(9):1019-26. PubMed ID: 26017303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous-use ethinylestradiol/levonorgestrel 20microg/90microg: as an oral contraceptive.
    Wagstaff AJ
    Drugs; 2007; 67(16):2473-7; discussion 2478-9. PubMed ID: 17983260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial.
    Archer DF; Stanczyk FZ; Rubin A; Foegh M
    Contraception; 2012 Jun; 85(6):595-601. PubMed ID: 22133660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women.
    Ragueneau-Majlessi I; Levy RH; Janik F
    Epilepsia; 2002 Jul; 43(7):697-702. PubMed ID: 12102671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimating systemic exposure to ethinyl estradiol from an oral contraceptive.
    Westhoff CL; Pike MC; Tang R; DiNapoli MN; Sull M; Cremers S
    Am J Obstet Gynecol; 2015 May; 212(5):614.e1-7. PubMed ID: 25511238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.